A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus

Trial Profile

A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus Erythematosus

Active, no longer recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 12 Oct 2017

At a glance

  • Drugs Belimumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Therapeutic Use
  • Acronyms EMBRACE; SLE EMBRACE
  • Sponsors GlaxoSmithKline; Human Genome Sciences
  • Most Recent Events

    • 09 Oct 2017 Planned End Date changed from 14 Feb 2019 to 11 Feb 2019.
    • 09 Oct 2017 Planned primary completion date changed from 2 Aug 2018 to 2 Jul 2018.
    • 09 Oct 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top